Synopsis
Plan and assess a trial without catheter using the original indication, realistic voiding observations and a prompt rescue pathway.
- A trial without catheter tests comfortable effective emptying after removal; one small void is insufficient evidence of success.
- Review why the catheter was inserted before deciding that removal is safe, particularly after renal-threatening retention or urinary surgery.
- Offer an alpha blocker before catheter removal in suitable men with acute retention; assess the likely mechanism and prescribing contraindications.
Reasoning priorities
Clarify the original mechanism and any restriction on removal or reinsertion.
Record the initial retained volume, renal findings, catheter difficulty and relevant surgery. If the record suggests an artificial sphincter, urethral injury or reconstruction, obtain specialist direction before a routine trial or attempted rescue catheterisation.
Worked reasoning
A 67-year-old man returns after transient retention following non-urological surgery.
- His catheter initially drained 650 ml. He is now mobile, passing stool and off opioid analgesia, with normal renal results and no prior voiding symptoms; there is no urinary reconstruction requiring continued drainage.
- The nurse removes the catheter in a morning clinic with scanning and recatheterisation available. He drinks gradually within his usual allowance rather than rapidly consuming several litres.
- At three hours he voids 240 ml comfortably, with a prompt PVR of 75 ml. Because this is the first void and he remains in the clinic, the team observes further rather than declaring the trial complete from one measurement.
- He later passes 280 ml with a residual of 45 ml and no pain. These observed values, normal baseline renal status and resolved precipitant support discharge under the service’s documented criteria.
- Before leaving he repeats the advice to seek help for inability to void or painful distension and identifies the contact route. Follow-up confirms ongoing comfortable voiding without recurrent retention; no empirical prostate medicine is added solely because he is male.
Key medicines
Tamsulosin prolonged-release hard capsule400 micrograms orally once daily after breakfast or the first daily meal, swallowed intact. Start before catheter removal; review continuation following the trial and at the subsequent LUTS assessment.No universal number of pretrial doses is specified by CG97. Avoid with orthostatic hypotension history or severe hepatic insufficiency; caution below creatinine clearance 10 ml/min. This is not an automatic prescription for women, neurological retention or a purely transient postoperative episode. If cataract/glaucoma surgery is booked, initiation is not recommended. Communicate current and earlier tamsulosin treatment to the ophthalmic team.